Angiocidin (human), (recombinant)



ALX-522-451-C010	10 µg	371.00 USD

Shows sequence similarity with proteasome components and is also being referred to as 26A proteasome regulatory subunit S5A. Shows both matrix and cytoplasmic distribution. It binds to thrombospondin-1 and α2β1 integrin, and it inhibits tumor progression and angiogenesis. Expressed in various types of cancer, such as hepatocellular carcinoma, prostate, lung, bladder and melanoma cancers.

Product Specification

Alternative Name:	26S proteasome regulatory subunit S5A, 26S proteasome non-ATPase regulatory subunit 4, Rpn10, Multiubiquitin chain-binding protein, Antisecretory factor 1

Concentration:	0.1mg/ml after reconstitution.

Endotoxin Content:	<0.1EU/µg purified protein (LAL test; Lonza).

MW:	~50kDa (SDS-PAGE).

Purity:	≥95% (SDS-PAGE)

Formulation:	Lyophilized. Contains PBS.

Source/Host:	Produced in E. coli. Human Angiocidin (aa 2-377) is untagged.

Reconstitution:	Reconstitute with 100µl sterile water. PBS containing at least 0.1% BSA should be used for further dilutions.

Short Term Storage:	+4°C

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 6 months after receipt when stored at -20°C.

Handling:	After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Background / Technical Information:	UniProt ID O43242: Angiocidin (human)

General Literature References

The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor: A. Gaurnier-Hausser & G. P. Tuszynski; Curr. Pharm. Des. 15, 1937 (2009), Abstract;

Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1: J. Zhou, et al.; J. Cell. Biochem. 92, 125 (2004), Abstract;